Toxicity and adverse effects of Tamoxifen and other anti-estrogen drugs

被引：135

作者：

Yang, Geniey ^{[1
]}

Nowsheen, Somaira ^{[2
]}

Aziz, Khaled ^{[2
]}

Georgakilas, Alexandros G. ^{[1
,3
]}

机构：

[1] E Carolina Univ, Thomas Harriot Coll Arts & Sci, Dept Biol, Greenville, NC 27858 USA

[2] Mayo Clin, Coll Med, Mayo Grad Sch, Med Scientist Training Program, Rochester, MN 55905 USA

[3] Natl Tech Univ Athens, Sch Appl Math & Phys Sci, Dept Phys, GR-15773 Athens, Greece

来源：

PHARMACOLOGY & THERAPEUTICS | 2013年 / 139卷 / 03期

关键词：

Tamoxifen; DNA damage; Oxidative stress; Anti-estrogen therapy; Breast cancer; ADVANCED BREAST-CANCER; ESTROGEN-RECEPTOR MODULATORS; POSTMENOPAUSAL WOMEN; OXIDATIVE STRESS; POLY(ADP-RIBOSE) POLYMERASE; PROGESTERONE-RECEPTOR; PHYSICAL-ACTIVITY; RANDOMIZED-TRIAL; PARP INHIBITORS; JEWISH WOMEN;

D O I：

10.1016/j.pharmthera.2013.05.005

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Breast cancer is a heterogeneous disease affecting thousands of people every year. Multiple factors are responsible in causing breast cancer while a number of treatment options are also available for the disease. Tamoxifen is the most widely used anti-estrogen for the treatment of hormone-dependent breast cancer. The specific drug is used as a hormonal therapy for patients who exhibit estrogen receptor positive breast cancer. The pharmacological activity of Tamoxifen is dependent on its conversion to its active metabolite, endoxifen, by CYP2D6. Tamoxifen reduces the risk of recurrence and death from breast cancer when given as adjuvant therapy and provides effective palliation for patients with metastatic breast cancer. In this review we focus on the role of Tamoxifen in breast cancer treatment including mechanisms and side-effects. Finally, we discuss in detail the exciting prospects that lie ahead. (C) 2013 Elsevier Inc. All rights reserved.

引用

页码：392 / 404

页数：13

共 96 条

[1] Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer [J].

Agus, DB ;

Gordon, MS ;

Taylor, C ;

Natale, RB ;

Karlan, B ;

Mendelson, DS ;

Press, MF ;

Allison, DE ;

Sliwkowski, MX ;

Lieberman, G ;

Kelsey, SM ;

Fyfe, G .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (11) :2534-2543

[2] A synthetic lethal therapeutic approach: Poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair [J].

Ashworth, Alan .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (22) :3785-3790

[3] Targeting DNA damage and repair: Embracing the pharmacological era for successful cancer therapy [J].

Aziz, K. ;

Nowsheen, S. ;

Pantelias, G. ;

Iliakis, G. ;

Gorgoulis, V. G. ;

Georgakilas, A. G. .

PHARMACOLOGY & THERAPEUTICS, 2012, 133 (03) :334-350

[4] Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy [J].

Baselga, Jose ;

Gelmon, Karen A. ;

Verma, Shailendra ;

Wardley, Andrew ;

Conte, PierFranco ;

Miles, David ;

Bianchi, Giulia ;

Cortes, Javier ;

McNally, Virginia A. ;

Ross, Graham A. ;

Fumoleau, Pierre ;

Gianni, Luca .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (07) :1138-1144

[5] Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer [J].

Birgisdottir, Valgerdur ;

Stefansson, Olafur A. ;

Bodvarsdottir, Sigridur K. ;

Hilmarsdottir, Holmfridur ;

Jonasson, Jon G. ;

Eyfjord, Jorunn E. .

BREAST CANCER RESEARCH, 2006, 8 (04)

[6] Lung Cancer Mortality Risk Among Breast Cancer Patients Treated With Anti-Estrogens [J].

Bouchardy, Christine ;

Benhamou, Simone ;

Schaffar, Robin ;

Verkooijen, Helena M. ;

Fioretta, Gerald ;

Schubert, Hyma ;

Vinh-Hung, Vincent ;

Soria, Jean-Charles ;

Vlastos, Georges ;

Rapiti, Elisabetta .

CANCER, 2011, 117 (06) :1288-1295

[7] Hypoxia and oxidative stress in breast cancer - Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer [J].

Brown, NS ;

Bicknell, R .

BREAST CANCER RESEARCH, 2001, 3 (05) :323-327

[8] Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase [J].

Bryant, HE ;

Schultz, N ;

Thomas, HD ;

Parker, KM ;

Flower, D ;

Lopez, E ;

Kyle, S ;

Meuth, M ;

Curtin, NJ ;

Helleday, T .

NATURE, 2005, 434 (7035) :913-917

[9] Interaction with type II estrogen binding sites and antiproliferative activity of tamoxifen and quercetin in human non-small-cell lung cancer [J].

Caltagirone, S ;

Ranelletti, FO ;

Rinelli, A ;

Maggiano, N ;

Colasante, A ;

Musiani, P ;

Aiello, FB ;

Piantelli, M .

AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 1997, 17 (01) :51-59

[10] Genetic variants in epigenetic genes and breast cancer risk [J].

Cebrian, Arancha ;

Pharoah, Paul D. ;

Ahmed, Shahana ;

Ropero, Santiago ;

Fraga, Mario F. ;

Smith, Paula L. ;

Conroy, Don ;

Luben, Robert ;

Perkins, Barbara ;

Easton, Douglas F. ;

Dunning, Alison M. ;

Esteller, Manel ;

Ponder, Bruce A. J. .

CARCINOGENESIS, 2006, 27 (08) :1661-1669

← 1 2 3 4 5 6 7 8 9 10 →